19 results about "CDH1" patented technology

The invention relates to the field of cell engineering, in particular to application of CDH1 in promoting cell production and / or exosome release. According to the invention, after the lentiviral vector of the over-expressed CDH1 gene is constructed, tumor cells are transfected by the lentiviral vector, and finally the tumor cell strain capable of stably expressing CDH1 is obtained. Through extraction and detection, the cell strain obviously improves the yield of the exosome in unit cell and unit culture medium volume, and the yield of the exosome is obviously improved.

Molecular signature of a common alopecia state, associated with cell junctions. The present invention relates to a method for the in vitro prognosis and / or diagnosis of a common alopecia state of the scalp in a subject, in particular androgenetic alopecia, comprising at least one step a) of measuring the level of expression, in a biological sample taken from an area suspected of being an alopecia area or of becoming an alopecia area in said subject, of at least one gene selected from CDH1, ACTB, ACTBL2, TUBB, TUBB2A, GSN, MYO3B, MYO5B, MYO6, DSG2, DSG3, DSG4, DSC2, GJB2, GJA1, GJB6, GJA3, TJP2, CLDN8, CLDN10, CLDN19, and optionally of at least one gene selected from CTNNB1 and CTNND2.The invention also relates to an in vitro method for evaluating the effectiveness of a treatment for a common alopecia condition, a cosmetic treatment method, the use of a modulator of said gene(s) mentioned above, as well as a method for identifying a compound enabling the prevention and / or treatment of a common alopecia condition.

The present invention discloses a negative regulation mechanism, experimental method and application of the Agrin-MuSK-DOK7 signaling pathway. After Agrin stimulates myotubes to activate MuSK, MuSK promotes phosphorylation of DOK7 Tyr106. With the help of CDH1, APC2 binds to DOK7 phosphorylated at Tyr106 and mediates ubiquitination of DOK7 Lys243 mainly in the form of K48 connection, promoting the degradation of DOK7 through the proteasome system, and ultimately leading to downregulation of DOK7 protein level, thereby achieving negative regulation of the Agrin-MuSK-DOK7 signaling pathway. In the present invention, APC2 CDH1 By promoting the ubiquitination and degradation of DOK7, negative regulation of the Agrin-MuSK-DOK7 signaling pathway is achieved, avoiding excessive activation of the Agrin-MuSK-DOK7 signaling pathway leading to abnormal NMJ development. The present invention provides a new theoretical basis for a deeper understanding of the molecular mechanism of neuromuscular junction development, and also provides new ideas for the development of treatment methods for related diseases.

The invention discloses a mouse gastric adenocarcinoma cell line MPC as well as a construction method and application thereof, and belongs to the technical field of preparation of tumor cell lines and tumor models. The mouse gastric adenocarcinoma cell strain MPC is preserved in China Center for Type Culture Collection, has Cdh1 and Tp53 gene mutations at the same time, has stable cell biological characteristics and typical adenocarcinoma characteristics, can form tumors in immunodeficient and normal immune mice, can be used for preparing a mouse tumor model for occurrence, development and metastasis of gastric cancer, and has a good application prospect. The method is applied to important researches such as molecular biology, cytobiology, detection kit development, new drug research and development and the like.

The present invention relates to the systems and methods of identifying compounds to treat or prevent chronic obstructive pulmonary disorders (COPD). The present invention also provides compositions to treat or prevent COPD comprising modulators of one or more selected from the group consisting of: AC AN, ACTN1, ADAMTS4, ADRB2, AGER, AN06, AP3B1, AP0A1, ARRB1, ATP1A1, BCL2L1, BDKRB1, BRAF, CALCRL, CCL11, CDH1, CEACAM8, CHRM3, CHRNA1, CLU, COL10A1, COL12A1, COL14A1, COL4A2, COL6A1, COL6A3, COLGATE 1, CRH, CSK, CTSD, CTTN, CXCR1, CXCR4, CXCR5, FBN1, FGA, FGG, FHL2, FTH1, GNB1, GPIHBP1, GPR84, GPR97, GRM8, HAPLN1, H2BFS, HBB, HSP90B1, ICAM1, IGF1R, IL6, ITGA1, ITGAV, LAMA2, LAMA4, LRP1, LTBP1, MAPK3, MGAM, MMP1, MMP13, MMP3, MMP9, MYBPH, MYH10, MYH9, NMU, NR3C1, P4HB, PLCB3, PLAG2G7, POU2AF1, PPIB, PROK2, RUNX2, RXFP1, S100A12, S100P, SAA1, SDC2, SLC2A5, SMAD3, SPARCL1, SPP1, SYT13, TBX1, TF, TGFB2, THBS1, TIMP1, TLN1, TPM1, TPM2, TPM4, TSPAN14, TEN, TWIST2, VIM, and WT1, and methods of use thereof.

This article discloses a method for identifying the nature of thyroid nodules, including detecting the DNA methylation level in a sample selected from the following regions (1) and (2): (1) fragments of one or more of the following genes: GAS6, SOX17, ZMIZ1, TSHR, CDH1, MCRIP2, LINC01977, EGR3, and (2) nucleic acid regions within 10 kb upstream and downstream of the genes (1).

Disclosed is a method of treating cancer in a subject using cyclin-dependent kinases 4 / 6 inhibitors such as abemaciclib. In particular, the subject carries specific diffuse type driver pathway alterations including ARHGAP fusion and CDH1 mutation. In particular, the cancer is gastric cancer. Also provided is a system for testing drug sensitivity using gastric cancer organoid and the use of the system to identify biomarkers predicting sensitivity to CDK4 / 6 inhibitors in gastric cancer.

The application relates to the field of biotechnology, in particular to a probe composition for detecting a salivary gland tumor gene panel and application thereof, and further relates to a library construction method, a sequencing method, a kit and a device for the salivary gland tumor gene panel. The probe composition can capture nucleic acid molecules of multiple genes related to salivary gland tumors, such as AKT1, APC, AR, ARID1A, ATM, AXIN1, BAP1, BARD1, BCOR, BRAF, BRCA1, BRCA2, CDH1, CDK11B, CDKN2A, CDKN2B, CREBBP, CTNNB1, CYLD, EGFR and EP300. The nucleic acid molecules in a sample to be analyzed are captured by using the probe composition, and library construction and sequencing are carried out; and the analysis result of the sequencing data is helpful to improving the diagnosis accuracy of salivary gland tumors.

This invention relates to a composition for preventing colitis-associated colorectal cancer and controlling weight, comprising seahorse, laver, kelp, spirulina, Ulva procumbens, and Gracilaria in a specific ratio. This formula is based on traditional Chinese medicine theories such as "five colors entering the five internal organs," "five flavors entering the meridians," and "salt can soften hardness," while also considering the combined use of warming and cooling properties, and the integration of clearing and tonifying. Through the combination of various marine algae and seahorse, it achieves synergistic effects on multiple targets, including immune regulation, anti-inflammation, intestinal barrier repair, and weight control. The preparation method is simple and low-cost, suitable for large-scale production in food and dietary supplements. Animal experiments show that this composition can significantly slow weight gain in normal mice. In an AOM / DSS-induced colitis-associated colorectal cancer model, it can reduce the disease activity index, decrease the number of colon tumors, alleviate abnormal organ enlargement and intestinal pathological damage, downregulate inflammatory factors such as iNOS and Cox-2, and upregulate intestinal barrier-related factors such as Cdh1, demonstrating a good preventive intervention effect.

The invention relates to preparation and functional analysis of an anti-soluble human CDH1 nano antibody. Specifically, the invention provides a CDH1 protein targeting nano antibody, and the CDH1 protein targeting nano antibody comprises a CDR1 as shown in SEQ ID NO: 4, a CDR2 as shown in SEQ ID NO: 5, and a CDR3 as shown in SEQ ID NO: 6. The nano antibody has high affinity with CDH1 protein, has the characteristics of high stability, high water solubility and the like, can be used for developing pharmaceutical compositions for treating CDH1-mediated related diseases or symptoms, can also be used for developing CDH1 detection reagents or kits, provides potential efficient antibodies for research of CDH1-mediated related diseases, and has a wide application prospect. And a new treatment strategy and target are provided for tumors.

The present disclosure relates to a cosmetic composition containing an extract of Cyperus rotundus extracted using warm microbubbles. The extract inhibits nitric oxide (NO) production and exhibits excellent anti-inflammatory efficacy by inhibiting the expression of interleukin 6 (IL-6), cyclooxygenase-2 (COX-2), interleukin-1β (IL-1β), and tumor necrosis factor-α (TNF-α), which are inflammatory expression factors. In addition, the extract enhances the expression of aquaporin-3 (AQP-3), hyaluronan synthase 2 (HAS-2), claudin-1 (CLDN-1), cadherin 1 (CDH1), filaggrin (FLG), and involucrin (IVL), which are genes related to the skin barrier and moisturizing. Thus, when using the extract for cosmetic products, excellent effects can be exhibited in skin soothing, moisturizing, enhancement of the skin barrier, relief of irritation such as erythema, relief of pruritus, and the like, so the extract can be usefully applied to multi-care products that improve skin conditions.

The present application relates to the field of cell engineering, and particularly relates to the use of CDH1 in promoting the production and / or release of exosomes. After constructing a lentivirus vector overexpressing a CDH1 gene, the lentivirus vector is transfected into tumor cells, and finally a tumor cell strain stably expressing CDH1 is obtained. Through extraction and detection, the cell strain significantly improves the yield of exosomes per unit of cells and per unit of culture medium volume, and the yield of exosomes is significantly improved.

The present invention relates to a cosmetic composition containing a Cyperus rotundus extract extracted by heating microbubbles. The extract has excellent anti-inflammatory effects by suppressing the production of nitric oxide (NO) and the expression of inflammation-inducing factors IL-6 (interleukin 6), COX-2 (cyclooxygenase-2), IL-1β (interleukin-1β), and TNF-α (tumor necrosis factor-α). It also enhances the expression of skin impact and moisturizing genes AQP-3 (aquaporin-3), HAS-2 (hyaluronan synthase 2), CLDN-1 (claudin-1), CDH1 (cadherin 1), FLG (filaggrin), and IVL (involucrin). When used as a cosmetic, it has excellent effects on skin soothing, moisturizing, improving the skin barrier, easing irritation such as skin erythema, and relieving itching, and can be usefully used as a multi-care product that improves skin condition.

The invention relates to the field of cancer, in particular breast cancer. In particular it relates to the field of immune system directed approaches for tumor reduction and control. Some aspects of the invention relate to vaccines, vaccinations and other means of stimulating an antigen specific immune response against a tumor in individuals. Such vaccines comprise neoantigens resulting from frameshift mutations that bring out-of-frame sequences of the GATA3, CDH1, MAP3K1, RUNX1, and TP53 genes in-frame. Such vaccines are also useful for ‘off the shelf’ use.

A computer-implemented method may diagnose invasive lobular carcinoma. The method may include receiving one or more digital images into a digital storage device, applying a trained machine learning module to detect a presence or absence of CDH1 biallelic genetic inactivation and / or CDH1 biallelic mutation from the received one or more digital images, and determining whether the patient has invasive lobular carcinoma using the detected presence or absence of the CDH1 biallelic genetic inactivation and / or CDH1 biallelic mutation as ground truth. The one or more digital images may include images of breast tissue of a patient.

Methods for identifying and selecting algorithms usable for detecting tumors and / or cancers in patient samples are provided. In some embodiments, the methods include determining gene expression levels of one or more of FGFR1OP2, CDH1, TP53, PIK3CA, S100A8, FAXDC2, CLEC12A, DMTN, MUC1, PSPH, MALAT1, and MKI67 present in a biological sample isolated from the subject that has one or more tumor educated cells that have been contacted directly or indirectly by the tumor and / or the cancer. Disclosed methods include, but are not limited to, generating gene expression profiles predictive of diseases and / or disorders, inhibiting gene expression changes resulting from initiation and / or progression of diseases and / or disorders, inhibiting proliferation and / or survival of target cells, inhibiting epithelial mesenchymal transition (EMT), inhibiting platelet aggregation, and inhibiting loss of immune cell targeting ability, among others. Also provided are systems for use in the presently disclosed methods.

A computer-implemented method may diagnose invasive lobular carcinoma. The method may include receiving one or more digital images into a digital storage device, applying a trained machine learning module to detect a presence or absence of CDH1 biallelic genetic inactivation and / or CDH1 biallelic mutation from the received one or more digital images, and determining whether the patient has invasive lobular carcinoma using the detected presence or absence of the CDH1 biallelic genetic inactivation and / or CDH1 biallelic mutation as ground truth. The one or more digital images may include images of breast tissue of a patient.

Disclosed herein is a method of identifying the nature of a thyroid nodule, comprising detecting the level of DNA methylation in a sample in a region selected from (1) and (2) below: (1) a fragment of one or more genes selected from the group consisting of NEURL1, RUSC1, IL17C, TSHR, DAPK, PAX5, IRX4, CDH1, (2) a nucleic acid region within 10 Kb upstream or downstream of the genes of (1).

This article discloses a method for identifying the nature of thyroid nodules, including detecting the DNA methylation level in a sample selected from the following regions (1) and (2): (1) fragments of one or more of the following genes: RARG, PRR15, DPYS, MCC, TBX15, TSHR, DAPK, CDH1, and (2) nucleic acid regions within 10 kb upstream and downstream of the gene (1).